Company: INMB
Filing Date: 2025-03-07
Form Type: 424B5
Source: 0001213900-25-021719
Chunk: 0

Company: Inmune Bio, Inc.
Filing Date: 2025-03-07
Form: 424B5
Chunk 0
---
Filed Pursuant to Rule 424(b)(5)

Registration No. 333-279036

PROSPECTUS SUPPLEMENT

(To Prospectus dated August 7, 2024)

<div align='center'>Up to 3,898,852 Shares of Common Stock Underlying Previously Issued Warrants</div>

This prospectus relates to the issuance by INmune
Bio Inc. of up to 3,898,852 shares of our common stock issuable from time to time upon exercise of certain warrants that we previously
issued in our (i) registered direct offering that closed on April 19, 2024 (the “April 2024 Offering”), (ii) our registered
direct offering that closed on April 29, 2024 (the “Second April 2024 Offering”), and (iii) our registered direct offering
that closed on September 16, 2024 (the “September 2024 Offering” and together with the April 2024 Offering and the Second
April 2024 Offering, the “Offerings”).

The warrants include: (i) warrants issued in the
April 2024 Offering that are exercisable until the earlier of (a) April 24, 2026 or (b) thirty (30) trading days following the reporting
of top line data in the Company’s Phase 2 Alzheimer’s program of XPro1595, but not thereafter, provided however, in the
event that the warrant is held by directors, officers or other affiliates of the Company and the termination date is during a period that
such officers, directors or affiliates are subject to a blackout with respect to trading in the Company’s common stock, such officers,
directors or affiliates will have an additional 60 days from the termination of the blackout date to exercise the warrant and have an
exercise price of $9.152 per share for up to 571,592 shares of common stock (the “April 2024 Warrants”); (ii) warrants issued
in the Second April 2024 Offering that are exercisable until the earlier of (a) April 29, 2026 or (b) thirty (30) trading days following
the reporting of positive top line data (Early/mild Alzheimer’s Cognitive Composite (“EMACC”) with a p-value less than
or equal to 0.05) in the Company’s Phase 2 Alzheimer’s program of XPro1595 at an exercise price of $9.84 per share for